← Back to patent-cliff list
硫酸氢氯吡格雷/阿司匹林
Tier C — Watch / tradeClopidogrel Bisulfate/Aspirin
赛诺菲
Originator
2008
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：COXs、P2RY12
Brand：ComPlavin、DuoPlavin、Coplavix、PlavixA
Indications (approved)：动脉粥样硬化、急性冠脉综合征、血栓形成、心肌梗塞、心绞痛
Regional status
US
-
EU
批准上市
2010-03-14
China
批准上市
2021-09-30
Japan
批准上市
2013-09-20
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Clopidogrel Bisulfate/Aspirin?
Approved indications include: 动脉粥样硬化, 急性冠脉综合征, 血栓形成, 心肌梗塞, 心绞痛.
When does the Clopidogrel Bisulfate/Aspirin patent expire?
No public expiry year is available for Clopidogrel Bisulfate/Aspirin yet; this page updates once verified.
How do I get a quote for Clopidogrel Bisulfate/Aspirin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24